• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Unicycive Therapeutics, Inc. and Alarum Technologies Ltd. Interviews to Air on Bloomberg TV on the RedChip Money Report®

    6/9/23 9:00:00 AM ET
    $ALAR
    $UNCY
    Computer Software: Prepackaged Software
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALAR alert in real time by email

    ORLANDO, FL / ACCESSWIRE / June 9, 2023 / RedChip Companies will air new interviews with Unicycive Therapeutics, Inc. (NASDAQ:UNCY) and Alarum Technologies Ltd. (Nasdaq, TASE: ALAR) on The RedChip Money Report® on Bloomberg TV, this Saturday, June 10, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

    Access the interviews in their entirety at:

    • Unicycive Therapeutics, Inc. (NASDAQ:UNCY): https://uncyinfo.com/interview_access
    • Alarum Technologies Ltd.: https://alarinfo.com/interview_access

    About The RedChip Money Report®

    The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Relations and media firm with 30 years' experience focused on Discovering Tomorrow's Blue Chips Today™. "The RedChip Money Report®" delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.

    About Unicycive Therapeutics, Inc.

    Unicycive is focused on two kidney diseases with large unmet medical needs. We are developing Renazorb, an investigational phosphate binding agent using proprietary nanoparticle technology for the treatment of patients with hyperphosphatemia. We plan to file a New Drug Application (NDA) for Renazorb with the U.S. Food and Drug Administration (FDA) mid-year. We are also developing UNI-494, a new chemical entity with a novel mechanism of action that restores mitochondrial function in acute and chronic diseases. Our initial target for UNI-494 is acute kidney injury (AKI), for which there are currently no FDA-approved medicines. For more information, please visit www.unicycive.com.

    About Alarum Technologies Ltd.

    Alarum Technologies Ltd. (Nasdaq, TASE: ALAR) is a global provider of internet access solutions. The Company operates primarily in two distinct segments: solutions for enterprises and solutions for consumers.

    The solutions by NetNut, our Enterprise Internet Access arm, are based on our world's fastest and most advanced and secured hybrid proxy network, enabling our customers to collect data anonymously at any scale from any public sources over the web. Our network comprises both exit points based on our proprietary reflection technology and hundreds of servers located at our Internet Service Providers partners around the world. The infrastructure is optimally designed to guarantee privacy, quality, stability, and the speed of the service.

    Our Consumer Internet Access arm offers privacy and cybersecurity solutions to end users. These solutions are designed to allow users to take charge of their online privacy with a powerful, secured and encrypted connection. The solutions are designed for basic and advanced use cases, ensuring complete protection of personal and digital information.

    For more information about Alarum and its internet access solutions for enterprises and consumers, please visit www.alarum.io.

    About RedChip Companies

    RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 30 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, the RedChip Money Report is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, "The RedChip Money Report," which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.

    To learn more about RedChip's products and services, please visit:

    https://www.redchip.com/corporate/investor_relations

    "Discovering Tomorrow's Blue Chips Today"™

    Contact:

    Dave Gentry
    RedChip Companies Inc.
    1-800-RED-CHIP (733-2447)
    Or 407-491-4498
    [email protected]

    --END--

    SOURCE: RedChip



    View source version on accesswire.com:
    https://www.accesswire.com/760280/Unicycive-Therapeutics-Inc-and-Alarum-Technologies-Ltd-Interviews-to-Air-on-Bloomberg-TV-on-the-RedChip-Money-Report

    Get the next $ALAR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALAR
    $UNCY

    CompanyDatePrice TargetRatingAnalyst
    Unicycive Therapeutics Inc.
    $UNCY
    4/21/2025$6.00Buy
    Guggenheim
    Alarum Technologies Ltd.
    $ALAR
    8/26/2024$34.00 → $20.00Buy
    Alliance Global Partners
    Alarum Technologies Ltd.
    $ALAR
    7/25/2024$42.00Hold → Buy
    Canaccord Genuity
    Alarum Technologies Ltd.
    $ALAR
    7/3/2024$42.00Hold
    Canaccord Genuity
    Unicycive Therapeutics Inc.
    $UNCY
    4/4/2024$9.00Overweight
    Piper Sandler
    Unicycive Therapeutics Inc.
    $UNCY
    8/9/2021$13.50Buy
    Roth Capital
    More analyst ratings

    $ALAR
    $UNCY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 3 filed by new insider Weiss Omer

    3/A - Alarum Technologies Ltd. (0001725332) (Issuer)

    3/24/26 4:01:19 PM ET
    $ALAR
    Computer Software: Prepackaged Software
    Technology

    SEC Form 3 filed by new insider Weiss Omer

    3 - Alarum Technologies Ltd. (0001725332) (Issuer)

    3/19/26 4:01:19 PM ET
    $ALAR
    Computer Software: Prepackaged Software
    Technology

    SEC Form 3 filed by new insider Halfon Yehuda

    3 - Alarum Technologies Ltd. (0001725332) (Issuer)

    3/19/26 4:01:21 PM ET
    $ALAR
    Computer Software: Prepackaged Software
    Technology

    $ALAR
    $UNCY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

    Oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission under review by U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026Commercial readiness activities ongoing in anticipation of potential commercial launch of OLC in 3Q26As of March 30, 2026 unaudited cash, cash equivalents, and marketable securities totaled $54.9 million, with expected runway into 2027 LOS ALTOS, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the full year ended D

    3/30/26 7:05:00 AM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alarum Technologies Reports Fourth Quarter and Full Year 2025 Results

    Revenues for fourth quarter and full year 2025 of $11.8 million and $40.7 million, up 60% and 28% respectively, year-over-year; the strong growth driven by accelerating AI demand Investing strongly in enhancing capabilities, while remaining profitable with FY 2025 net profit of $1.0 million and adjusted EBITDA of $4.4 million TEL AVIV, Israel, March 19, 2026 (GLOBE NEWSWIRE) -- Alarum Technologies Ltd. (Nasdaq: ALAR, TASE: ALAR) ("Alarum" or the "Company"), a global provider of web data collection solutions, today announced its financial results for the fourth quarter and full year ended December 31, 2025. Financial Highlights of Full Year 2025 2025 revenues of $40.7 million, up 28% ye

    3/19/26 8:00:00 AM ET
    $ALAR
    Computer Software: Prepackaged Software
    Technology

    Alarum to Release Fourth Quarter & Full Year 2025 Results on March 19, 2026

    Conference call scheduled for Thursday, March 19, 2026, at 8:30 a.m. ET Tel Aviv, Israel, March 05, 2026 (GLOBE NEWSWIRE) -- Alarum Technologies Ltd. (NASDAQ:ALAR, TASE: ALAR)), a global provider of web data collection solutions, will release its financial results for the fourth quarter and full year ended December 31, 2025, before the Nasdaq market opens on Thursday, March 19, 2026. Mr. Shachar Daniel, Chief Executive Officer, and Mr. Shai Avnit, Chief Financial Officer, will host a conference call that same day at 8:30 a.m. ET to discuss the financial results and business outlook, followed by a Q&A session. To join the live call, please dial one of the numbers below or connect throug

    3/5/26 8:30:00 AM ET
    $ALAR
    Computer Software: Prepackaged Software
    Technology

    $ALAR
    $UNCY
    SEC Filings

    View All

    Unicycive Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Unicycive Therapeutics, Inc. (0001766140) (Filer)

    3/30/26 7:29:20 AM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Unicycive Therapeutics Inc.

    10-K - Unicycive Therapeutics, Inc. (0001766140) (Filer)

    3/30/26 6:32:02 AM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 20-F filed by Alarum Technologies Ltd.

    20-F - Alarum Technologies Ltd. (0001725332) (Filer)

    3/19/26 8:07:35 AM ET
    $ALAR
    Computer Software: Prepackaged Software
    Technology

    $ALAR
    $UNCY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Unicycive Therapeutics with a new price target

    Guggenheim initiated coverage of Unicycive Therapeutics with a rating of Buy and set a new price target of $6.00

    4/21/25 8:39:22 AM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alliance Global Partners reiterated coverage on Alarum Technologies Ltd. with a new price target

    Alliance Global Partners reiterated coverage of Alarum Technologies Ltd. with a rating of Buy and set a new price target of $20.00 from $34.00 previously

    8/26/24 12:41:01 PM ET
    $ALAR
    Computer Software: Prepackaged Software
    Technology

    Alarum Technologies Ltd. upgraded by Canaccord Genuity with a new price target

    Canaccord Genuity upgraded Alarum Technologies Ltd. from Hold to Buy and set a new price target of $42.00

    7/25/24 6:16:35 AM ET
    $ALAR
    Computer Software: Prepackaged Software
    Technology

    $ALAR
    $UNCY
    Financials

    Live finance-specific insights

    View All

    Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update

    Oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission under review by U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026Commercial readiness activities ongoing in anticipation of potential commercial launch of OLC in 3Q26As of March 30, 2026 unaudited cash, cash equivalents, and marketable securities totaled $54.9 million, with expected runway into 2027 LOS ALTOS, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the full year ended D

    3/30/26 7:05:00 AM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alarum Technologies Reports Fourth Quarter and Full Year 2025 Results

    Revenues for fourth quarter and full year 2025 of $11.8 million and $40.7 million, up 60% and 28% respectively, year-over-year; the strong growth driven by accelerating AI demand Investing strongly in enhancing capabilities, while remaining profitable with FY 2025 net profit of $1.0 million and adjusted EBITDA of $4.4 million TEL AVIV, Israel, March 19, 2026 (GLOBE NEWSWIRE) -- Alarum Technologies Ltd. (Nasdaq: ALAR, TASE: ALAR) ("Alarum" or the "Company"), a global provider of web data collection solutions, today announced its financial results for the fourth quarter and full year ended December 31, 2025. Financial Highlights of Full Year 2025 2025 revenues of $40.7 million, up 28% ye

    3/19/26 8:00:00 AM ET
    $ALAR
    Computer Software: Prepackaged Software
    Technology

    Alarum to Release Fourth Quarter & Full Year 2025 Results on March 19, 2026

    Conference call scheduled for Thursday, March 19, 2026, at 8:30 a.m. ET Tel Aviv, Israel, March 05, 2026 (GLOBE NEWSWIRE) -- Alarum Technologies Ltd. (NASDAQ:ALAR, TASE: ALAR)), a global provider of web data collection solutions, will release its financial results for the fourth quarter and full year ended December 31, 2025, before the Nasdaq market opens on Thursday, March 19, 2026. Mr. Shachar Daniel, Chief Executive Officer, and Mr. Shai Avnit, Chief Financial Officer, will host a conference call that same day at 8:30 a.m. ET to discuss the financial results and business outlook, followed by a Q&A session. To join the live call, please dial one of the numbers below or connect throug

    3/5/26 8:30:00 AM ET
    $ALAR
    Computer Software: Prepackaged Software
    Technology

    $ALAR
    $UNCY
    Leadership Updates

    Live Leadership Updates

    View All

    Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD

    LOS ALTOS, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the "Company" or "Unicycive"), today announced the appointment of Sara Kenkare-Mitra, PhD to the Company's Board of Directors, effective September 6, 2023. As a veteran of the biotech and pharmaceutical industry, we believe Sara's leadership and experience in drug development spanning more than 25 years will significantly help bolster Unicycive's future growth. "We are thrilled to welcome Dr. Kenkare-Mitra to our Board of Directors and know that her extensive drug development and corporate leadersh

    9/6/23 7:03:00 AM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alarum Releases Preliminary Guidance on Key Financial Metrics for the Second Quarter of 2023

    Anticipates 10th Consecutive Increase in Revenue and Growth in Adjusted EBITDA Alarum Further Reports on Implementation of Strategic Decisions Regarding Business Segments and Operations Tel Aviv, Israel, July 06, 2023 (GLOBE NEWSWIRE) -- Alarum Technologies Ltd. (Nasdaq, TASE: ALAR) ("Alarum" or the "Company"), a global provider of enterprise and consumers internet access solutions, today provided preliminary guidance on key financial metrics for the second quarter ended June 30, 2023. Based on a preliminary, unaudited review, Alarum anticipates reporting strong performance in the second quarter of 2023, highlighting continued growth and business success: Expects to report its

    7/6/23 8:30:00 AM ET
    $ALAR
    Computer Software: Prepackaged Software
    Technology

    Unicycive Therapeutics Appoints Douglas Jermasek As Executive Vice President, Corporate Strategy

    LOS ALTOS, Calif., Oct. 26, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced the appointment of Douglas Jermasek as Executive Vice President, Corporate Strategy. In this role, Mr. Jermasek, a seasoned healthcare professional, will have responsibility for Unicycive's corporate and commercial strategy and business development activities. Doug has spent the majority of his career focused on drugs for treatment of kidney diseases"With a career spent in heal

    10/26/21 7:30:00 AM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALAR
    $UNCY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Unicycive Therapeutics Inc.

    SC 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)

    11/14/24 7:13:38 PM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Unicycive Therapeutics Inc.

    SC 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)

    11/14/24 7:01:14 PM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Unicycive Therapeutics Inc.

    SC 13G/A - Unicycive Therapeutics, Inc. (0001766140) (Subject)

    11/14/24 5:46:12 PM ET
    $UNCY
    Biotechnology: Pharmaceutical Preparations
    Health Care